Stoke Therapeutics (NASDAQ:STOK) Downgraded to Sell Rating by Wall Street Zen

Stoke Therapeutics (NASDAQ:STOK) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also issued research reports about the company. Wedbush increased their target price on Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Tuesday. Wolfe Research assumed coverage on Stoke Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price target on the stock. Loop Capital set a $35.00 price target on Stoke Therapeutics in a report on Monday, January 5th. HC Wainwright increased their price objective on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, Needham & Company LLC lifted their price objective on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.83.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $33.51 on Friday. The business’s 50-day moving average is $32.61 and its two-hundred day moving average is $30.02. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $40.22. The firm has a market capitalization of $1.98 billion, a PE ratio of 50.01 and a beta of 1.07.

Insider Buying and Selling

In other news, insider Arthur Tzianabos sold 4,355 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total value of $174,200.00. Following the completion of the sale, the insider directly owned 31,339 shares in the company, valued at approximately $1,253,560. The trade was a 12.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Thomas Leggett sold 2,382 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $74,651.88. Following the sale, the chief financial officer directly owned 10,172 shares in the company, valued at approximately $318,790.48. This represents a 18.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 69,699 shares of company stock worth $2,526,714. 9.50% of the stock is currently owned by insiders.

Institutional Trading of Stoke Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Kestra Advisory Services LLC acquired a new position in shares of Stoke Therapeutics in the 4th quarter valued at about $26,000. Harbour Investments Inc. raised its stake in Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after acquiring an additional 898 shares during the period. Generali Investments Management Co LLC bought a new position in Stoke Therapeutics in the third quarter worth about $41,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Stoke Therapeutics by 31.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after acquiring an additional 658 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after acquiring an additional 1,668 shares during the period.

Key Stoke Therapeutics News

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.